Moderna, a lead player in bio-tech, seems to be ramping up efforts in vaccine discovery, with mRNA being the core driving factor. The firm was recently awarded a staggering
$590 million by the US government to speed up the development of its mRNA-based bird flu vaccine. Interestingly, as per chatter on Reddit, Moderna’s stock (MRNA) piqued interest as a potentially moon-bound stock. Despite a general slowdown in vaccine demand, the company seems undeterred in its pursuit of revolutionary breakthroughs. Ongoing development and trials of norovirus vaccines, experimental mRNA-1273 vaccine, and even a stomach flu vaccine are indicative. Despite the pause in Pediatric RSV vaccine trials due to safety signal concerns, optimism remains largely unhurt. However, despite these developments, Moderna has been in the financial red with weak stock performance and dwindled sales forecasts. The company announced planned cost cuts of up to $1.5 billion in hopes of a turnaround. Yet among these storms, Moderna surprised with profits driven by impressive COVID-19 vaccine sales and cost-cutting measures, causing its stock to rally briefly. Finally, amidst GSK’s patent infringement claims against Moderna’s mRNA vaccines and Northwestern University's royalty lawsuit, the company remains focused on their novel vaccine research.
Moderna MRNA News Analytics from Wed, 03 Apr 2024 07:00:00 GMT to Sat, 18 Jan 2025 14:37:47 GMT -
Rating -4
- Innovation 8
- Information 7
- Rumor -3
